Painful Diabetic Peripheral Neuropathy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Painful Diabetic Peripheral Neuropathy characteristically presents with a tingling sensation, numbness, burning, excruciating stabbing type of pain, sometimes intractable. It may be associated with paraesthesia and hyperesthesia coupled with deep aching in the feet or hands. Poor glycaemic control is a major risk factor for the development of diabetic neuropathy. It has been observed that an estimated 50% of patients develop Painful Diabetic Peripheral Neuropathy 25 years after the initial diagnosis of diabetes mellitus. The prevalence of PDN ranges from 10% to 20% of patients with diabetes, and in those with diabetic neuropathy, it ranges from 40% to 50%. The underlying mechanism for the generation of pain is hyperexcitability in primary afferent nociceptors, which occurs due to damage to peripheral nerves. This in turn, leads to hyperexcitability in central neurons and the generation of spontaneous impulses within the axon and the dorsal root ganglion of these peripheral nerves.
·
The ~26% to 52% of diabetic patients develop
Painful Diabetic Peripheral Neuropathy. Prevalence results included both
painful and nonpainful diabetic peripheral neuropathy.
Thelansis’s “Painful Diabetic
Peripheral Neuropathy Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Painful
Diabetic Peripheral Neuropathy treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Painful Diabetic Peripheral Neuropathy across the 8 MM market from the
centre of Excellence/ Public/ Private hospitals participated in the study.
Insights around current treatment landscape, epidemiology, clinical
characteristics, future treatment paradigm, and Unmet needs.
Painful Diabetic Peripheral Neuropathy
Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment